ACB — Aurora Cannabis Inc.

Aurora Cannabis Inc. Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: Increased by 11% year-over-year to $90 million, with global medical cannabis revenue rising 15% and international revenue up 22%.
• Adjusted Gross Margin: Improved by 700 basis points to 61%, with medical cannabis margins reaching 69%.
• Adjusted EBITDA: Rose 52% to $15 million, significantly outpacing revenue growth.
• Cash Position: Ended the quarter with $142 million in cash and no cannabis-related debt.
• Free Cash Flow: Negative $42.3 million, worsened from negative $26.4 million year-over-year, typical for Q2 cash outflows.

2. Strategic Updates and Business Highlights

• Aurora is focused on global medical cannabis, emphasizing high-margin segments and operational efficiencies.
• The company holds a leading position in key international markets, including Germany, Australia, Poland, and the U.K.
• Investments in GMP-certified facilities in Canada and Germany enhance their ability to supply high-quality products globally.
• Aurora is expanding production capacity in Germany and leveraging its established reputation to gain market share.
• The company is exploring emerging markets and adapting to regulatory changes, particularly in Germany and Poland.

3. Forward Guidance and Outlook

• For Q3 2026, Aurora expects consolidated net revenue growth of 8% to 12% driven by the medical cannabis segment.
• Adjusted gross margins are anticipated to remain strong, with positive free cash flow expected due to improved operating cash yield.

4. Bad News, Challenges, or Points of Concern

• Canadian Market: Proposed changes to veteran reimbursement rates could disrupt patient access and continuity of care, with potential negative impacts on revenue.
• Competitive Pressures: Increased competition in the Australian market, particularly in the value segment, is affecting sales.
• Regulatory Risks: Potential changes in Germany regarding telehealth and delivery regulations could pose challenges, especially for rural patients.
• Plant Propagation Segment: Revenue decreased year-over-year due to inventory write-offs and surplus crops, impacting margins.

5. Notable Q&A Insights

• Management indicated that production costs are decreasing, contributing to better-than-expected margins, with efficiencies gained from consistent cultivars across markets.
• Concerns were raised about the competitive landscape in Germany, where regulatory hurdles are affecting other companies but not Aurora due to its strong compliance and certification.
• In Australia, the transition to higher-margin products is ongoing, but the market is currently pressured by value product competition.
• The timeline for regulatory changes in Germany is uncertain, with significant debates expected in the coming months, while developments in Australia remain more open-ended without immediate timelines.

Overall, Aurora Cannabis reported strong financial performance driven by its strategic focus on medical cannabis, although it faces regulatory and competitive challenges that could impact future growth.